Brief Report

Padala, Prasad R.; Qadri, Sabreena; Madaan, Vishal

doi:10.4088/pcc.v07n0605

Cited by 17 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are too many case reports regarding the use of second-generation antipsychotic drugs in TS treatment, but limited numbers of open and case-controlled studies (4)(5)(6)13). Another antipsychotic drug shown to be clinically useful in TS with case reports recently is aripiprazole (11,12,14). While TS etiology is not known exactly, it is considered that many neurotransmitter systems play role in TS etiology.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case of tourette’s disorder responded to aripiprazole treatment

Şengül¹

2010

Dusunen Adam

View full text Add to dashboard Cite

Aripiprazol tedavisine yanıt veren bir Tourette bozukluğu olgusu Tourette bozukluğu, motor ve vokal tiklerle seyreden nöropsikiyatrik bir sendromdur. Özellikle haloperidol ve pimozid olmak üzere, antipsikotik ilaçlar Tourette bozukluğu tedavisinde uzun süredir kullanılmaktadır. Yapılan son çalışmalarda, Tourette bozukluğu tedavisinde ikinci kuşak antipsikotik ilaçların başarılı bir şekilde kullanıldığı bildirilmektedir. Biz bu yazımızda, aripiprazol tedavisi ile tikleri düzelen bir Tourette bozukluğu olgusunu sunmayı amaçladık.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In limited number of studies related to use of aripiprazole in TS treatment, favorable results were reported in general. Padala et al stated that two patients with TS benefited from aripiprazole treatment (11). Also Davies et al observed improvement in symptoms of 10 out of 11 TS patients using 10-20 mg aripiprazole (12).…”

Section: Introductionmentioning

confidence: 99%

A case of tourette’s disorder responded to aripiprazole treatment

Şengül¹

2010

Dusunen Adam

View full text Add to dashboard Cite

show abstract

“…Both patients were treated with aripiprazole and showed substantial resolution of symptoms with no reported side effects. 39 Djebara et al reported a more severe case in France of a 28-year-old man with severe coprolalia and hypersensitivity to neuroleptics. The use of aripiprazole as a last resort was well tolerated and induced a 75% improvement in symptoms.…”

Section: Case Reportsmentioning

confidence: 97%

Aripiprazole for the Treatment of Adolescent Tourette’s Syndrome

Lewis

Rappa

Sherwood-Jachimowicz

et al. 2010

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Gilles de la Tourette syndrome (GTS) is a neuropsychiatric, lifelong disorder with onset in childhood. The essential features of this disorder are multiple motor tics and one or more vocalizations. The neurochemical pathophysiology of GTS involves an unknown abnormality in the central dopaminergic system. Atypical antipsychotics, such as aripiprazole, serve as a new therapeutic option for GTS. The authors describe a unique case of Tourette's syndrome (TS) in an adolescent in which aripiprazole resolved the patient's symptoms. A 17-year-old, 5'11'' tall, African American male weighing 220 lbs was diagnosed with TS at 9 years old. By age 16, the patient developed prominent symptoms of intermitted eye blinking, forehead raising, finger snapping, heavy breathing, and head bobbing. Clonidine, in addition to homeopathic remedies (N-acetylcholine and alpha lipoic acid), was administered to the patient without significant diminution of symptoms. Later, aripiprazole was initiated at 5 mg/d. As a result, noticeable symptomatic improvement occurred within 48 hours. Aripiprazole was titrated over the next 4 weeks to 6.5 mg/d, with significant results. Over the next 6 months, aripiprazole was titrated again to 10 mg/d with additional symptom reduction. This case illustrates a patient who responded to aripiprazole with no reported adverse effects, when standard therapy failed to improve symptoms.

show abstract

“…Since 2004, various reports exploring the efficacy and safety of aripiprazole in the treatment of tics in GTS have been published. These include 28 case reports (Hounie et al, 2004 ; Dehning et al, 2005 ; Kastrup et al, 2005 ; Murphy et al, 2005 , 2009 ; Padala et al, 2005 ; Bubl et al, 2006 ; Constant et al, 2006 ; Davies et al, 2006 ; Duane, 2006 ; Fountoulakis et al, 2006 ; Yoo et al, 2006 , 2007 ; Ben Djebara et al, 2008 ; Budman et al, 2008 ; Findling et al, 2008 ; Seo et al, 2008 ; Winter et al, 2008 ; Ikenouchi-Sugita et al, 2009 ; Kawohl et al, 2009 ; Lai, 2009 ; Lyon et al, 2009 ; Cui et al, 2010 ; Frölich et al, 2010 ; Masi et al, 2012 ; Wenzel et al, 2012 ; Diomšina et al, 2015 ; Mazlum et al, 2015 ), 3 controlled trials (Gulisano et al, 2011 ; Yoo et al, 2013 ; Ghanizadeh and Haghighi, 2014 ), and 1 systematic review (Ghanizadeh, 2012 ). However, less than 40% of these reports have investigated the effects of aripiprazole on adult populations.…”

Section: Introductionmentioning

confidence: 99%

Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome

et al. 2016

View full text Add to dashboard Cite

Gilles de la Tourette Syndrome (GTS) is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU), and quality of life (QoL). Moreover, we were interested in the factors that influence a patient's decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. Eighteen out of fortyfour patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4–6 weeks. Our major findings were (1) aripiprazole resulted in significant reduction of tics, but did not affect PU; (2) aripiprazole significantly improved OCD and showed a trend toward improvement of other comorbidities including depression, anxiety, and ADHD; (3) neither severity of tics, nor PU or QoL influenced patients' decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4) most frequently reported adverse effects were sleeping problems; (5) patients' QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics in patients with GTS. It can be hypothesized that these beneficial effects are related to aripiprazole's adaptive pharmacological profile, which exhibits an influence on the dopaminergic as well as a number of other neurotransmitter systems. For the first time, our data provide evidence that patients' decision making process for or against medical treatment is influenced by other factors than tic severity and QoL.

show abstract

Brief Report

Cited by 17 publications

References 30 publications

A case of tourette’s disorder responded to aripiprazole treatment

A case of tourette’s disorder responded to aripiprazole treatment

Aripiprazole for the Treatment of Adolescent Tourette’s Syndrome

Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome

Contact Info

Product

Resources

About